Healthcare entity
Exact Sciences is most often covered alongside Seeking Alpha, which appears in 2 of these 4 stories. They are less corroborated than the beat average, carrying 2.5 original sources each against 4.3 for the same window. The 131-day window averages about 0.2 stories each week.
Last mentioned: Jul 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Exact Sciences is most often covered alongside Seeking Alpha, which appears in 2 of these 4 stories. They are less corroborated than the beat average, carrying 2.5 original sources each against 4.3 for the same window. The 131-day window averages about 0.2 stories each week. At 5.8, the average consequence score sits below the same-window beat average of 6.2. Coverage clusters in market-trends, which accounts for 2 of those 4, with the remainder spread across 1 other category. Exact Sciences appears in 4 tracked Healthcare stories published from March 14, 2026 through July 22, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 468 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Exact Sciences. Shared-story counts are live from our verified record — not editorial picks.
Global Milestone Announcement
Gene Solutions issues press release detailing ASCO recognition, FDA designation, and IPO plans, marking a turning point for the company.
FDA Breakthrough Device Designation
The U.S. FDA grants Breakthrough Device Designation to SPOT-MAS 10, acknowledging its potential to address unmet needs in cancer screening.
ASCO Breakthrough 2026
Gene Solutions presents interim real-world data from 84,145 asymptomatic individuals for SPOT-MAS 10 at the ASCO Breakthrough conference in Singapore.
A massive real-world study and FDA Breakthrough Device Designation position SPOT-MAS 10 as a potential paradigm shift in multi-cancer screening across Asian healthcare systems, offering a non-invasive, population-validated tool to combat rising cancer burdens.
Source: thehindubusinessline.com · thehindu.com
Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.
A sharp sell-off in mid-cap healthcare stocks has pushed several key players into technically oversold territory as geopolitical tensions in the Middle East trigger a broader market retreat. Investors are rotating out of riskier mid-sized equities, creating potential entry points for value-oriented healthcare analysts.
Source: Seeking Alpha
Mid-cap healthcare stocks are seeing a significant re-rating as quantitative models prioritize profitable growth and upward analyst revisions. Following a strong earnings season, the diagnostic and med-tech sub-sectors have emerged as the primary drivers of sector outperformance.
Source: Seeking Alpha · Seeking Alpha
Exact Sciences is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
